Severe haematological involvement in children with systemic lupus erythematosus and clinical associations

Rheumatology (Oxford). 2025 Apr 1;64(4):2153-2161. doi: 10.1093/rheumatology/keae414.

Abstract

Objectives: To investigate the severe haematological involvement in children with SLE and assess its clinical associations, treatments, outcome and damage accrual.

Methods: The medical charts of children with SLE in whom haematological involvement was observed were reviewed. Severe haematological indices were defined as autoimmune haemolytic anaemia with a haemoglobin concentration <8 g/dl, thrombocyte count <30 000/µL and neutrophil count <500/µL.

Results: Among the 224 patients included, 102 (45.5%) displayed severe indices, predominantly at the initial involvement, and most frequently as severe anaemia in 54 (24.1%) and severe thrombocytopenia in 45 (20.1%). Disease activity did not differ according to the presence of severe disease indices. In addition, the presence of severe indices at initial involvement did not affect the damage accrual. However, a higher rate of damage (51.1% vs 29.9%, P = 0.002) and steroid-induced damage (28.9% vs 8.2%, P < 0.001) was evident in patients with flares of the haematological system. Regression analysis revealed that rituximab treatment during the initial episode (OR: 4.5, P = 0.006) and the presence of anticardiolipin antibodies (OR: 2.3, P = 0.014) significantly increases the odds for haematological system flare. However, severe indices at initial involvement did not increase the odds of a haematological flare.

Conclusion: Severe haematological indices at onset are common but not related with disease outcomes. Prevention of flares is important to improve outcomes, and a more rigorous maintenance strategy would benefit most to children who display haematological indices refractory to conventional immunosuppressants and those with anti-cardiolipin antibodies.

Keywords: children; damage; flare; haematological involvement; systemic lupus erythematosus; treatment.

MeSH terms

  • Adolescent
  • Anemia, Hemolytic, Autoimmune* / blood
  • Anemia, Hemolytic, Autoimmune* / etiology
  • Antibodies, Anticardiolipin / blood
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Lupus Erythematosus, Systemic* / blood
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / drug therapy
  • Male
  • Platelet Count
  • Retrospective Studies
  • Rituximab / therapeutic use
  • Severity of Illness Index
  • Thrombocytopenia* / etiology

Substances

  • Rituximab
  • Antibodies, Anticardiolipin